arginine vasopressin has been researched along with pyrroles in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (13.33) | 18.2507 |
2000's | 17 (56.67) | 29.6817 |
2010's | 9 (30.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Eichinger, MR; Russ, RD; Walker, BR | 1 |
Albright, JD; Bailey, T; Chan, PS; Coupet, J; Delos Santos, EG; Dusza, JP; Mazandarani, H; Reich, MF; Ru, X; Sum, FW; Venkatesan, AM | 1 |
Albright, JD; Bailey, T; Cervoni, P; Chan, PS; Coupet, J; Dusza, JP; Hartupee, D; Lai, F; Lock, TY; Mazandarani, H; Ning, X; Ochalski, L; Park, HC; Ru, X; Shepherd, C; Spinelli, W; Tanikella, T; Taylor, JR | 1 |
Abraham, WT; Lieming, X; Martin, PY; Ohara, M; Olson, BR; Oren, RM; Schrier, RW | 1 |
Angers, S; Arthus, MF; Bernier, V; Bichet, DG; Bouvier, M; Laperrière, A; Lonergan, M; Morello, JP; Morin, D; Petäjä-Repo, U; Salahpour, A | 1 |
Atkinson, AJ; Champoux, M; Chrousos, GP; Contoreggi, C; Gold, PW; Habib, KE; Higley, JD; Listwak, S; McCann, SM; Pushkas, J; Rice, KC; Schulkin, J; Suomi, SJ; Webster, EL; Weld, KP | 1 |
Thibonnier, M | 1 |
Pham, PC; Pham, PM; Pham, PT | 1 |
Hantash, BM; Reeves, JP; Thomas, AP | 1 |
Verbalis, JG | 1 |
Omland, T; Solberg, OG | 1 |
Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
Balk, RA; Patel, GP | 1 |
Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
Haskal, R | 1 |
Bech, JN; Holm, C; Paulsen, L; Pedersen, EB; Starklint, J | 1 |
Schweiger, TA; Zdanowicz, MM | 1 |
Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT | 1 |
Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC | 1 |
Kumar, SK; Mather, PJ | 1 |
Goldsmith, SR | 1 |
Berrendero, F; de Lecea, L; Maldonado, R; Martín-García, E; Plaza-Zabala, A | 1 |
Ghali, JK; Tam, SW | 1 |
Daifallah, S; Farah, JO; Ghali, JK; Zmily, HD | 1 |
Cantillo, DS; Comín Colet, J; Robledo, GG | 1 |
Daifallah, S; Ghali, JK; Khan, NS; Zmily, HD | 1 |
Aimiuwu, O; Friedman, TC; Gomez, R; Liu, Y; Lutfy, K; Mangubat, M; Nerio, N; Shin, CS | 1 |
Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB | 1 |
Iwao, H; Izumi, Y; Miura, K | 1 |
Acaz-Fonseca, E; Garcia-Segura, LM; Ghorbanpoor, S; Grassi, D; Ruiz-Palmero, I | 1 |
19 review(s) available for arginine vasopressin and pyrroles
Article | Year |
---|---|
VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Blood Pressure; Cyclic AMP; Dogs; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney; Pyrroles; Receptors, Vasopressin | 1998 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2003 |
Vasopressin excess and hyponatremia.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan; Water-Electrolyte Balance | 2006 |
AVP receptor antagonists as aquaretics: review and assessment of clinical data.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan; Water-Electrolyte Balance | 2006 |
[Arginine vasopressin antagonism--new treatment option in chronic heart failure].
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Nephrons; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Vasoconstrictor Agents | 2007 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Critical Illness; Humans; Hyponatremia; Inpatients; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2007 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
Current issues for nurse practitioners: Hyponatremia.
Topics: Aged; Algorithms; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Causality; Decision Trees; Diagnosis, Differential; Early Diagnosis; Female; Homeostasis; Humans; Hyponatremia; Nurse Practitioners; Nurse's Role; Nursing Assessment; Patient Selection; Primary Health Care; Pyrroles; Tolvaptan; Water-Electrolyte Balance | 2007 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Hyponatremia; Infusions, Intravenous; Male; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Risk Assessment; Survival Rate; Tolvaptan; Water-Electrolyte Imbalance | 2008 |
Pharmacology of vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Benzodiazepines; Heart Failure; Humans; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2009 |
AVP receptor antagonists in patients with CHF.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Sodium | 2009 |
Treatment options for hyponatremia in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Pyrroles; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2009 |
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance | 2010 |
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Clinical Trials as Topic; Dogs; Heart Failure; Humans; Hyponatremia; Pyrroles; Rats | 2010 |
[Hyponatremia in heart failure: physiopathology and pharmacological approach].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Brain Edema; Demyelinating Diseases; Diuresis; Diuretics; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Kidney; Multicenter Studies as Topic; Natriuresis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Saline Solution, Hypertonic; Sympathetic Nervous System; Tolvaptan | 2010 |
The potential role for lixivaptan in heart failure and in hyponatremia.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Heart Failure; Humans; Hyponatremia; Plasma Volume; Pyrroles | 2011 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
4 trial(s) available for arginine vasopressin and pyrroles
Article | Year |
---|---|
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
Topics: Administration, Oral; Animals; Arginine Vasopressin; Azepines; Benzamides; Blood Platelets; Body Water; Cell Line; Cell Membrane; Dogs; Fibroblasts; Humans; Kidney; Liver; Osmolar Concentration; Pyrroles; Rats; Receptors, Vasopressin; Sodium; Structure-Activity Relationship; Urine | 1998 |
Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure.
Topics: Administration, Oral; Aged; Aquaporin 2; Aquaporin 6; Aquaporins; Arginine Vasopressin; Azepines; Benzamides; Biomarkers; Blotting, Western; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Pyrroles; Reference Values; Sensitivity and Specificity | 1999 |
Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
Topics: Adult; Angiotensin II; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diuresis; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Tubules; Male; Natriuresis; Natriuretic Peptide, Brain; Pyrroles; Renal Plasma Flow | 2008 |
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins | 2014 |
7 other study(ies) available for arginine vasopressin and pyrroles
Article | Year |
---|---|
Potassium channels are not involved in vasopressin-induced vasodilation in the rat lung.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Arginine; Arginine Vasopressin; Barium; Benzopyrans; Cromakalim; Glyburide; In Vitro Techniques; Kinetics; Lung; Male; Muscle, Smooth, Vascular; Nitroarginine; Potassium Channel Blockers; Potassium Channels; Prostaglandin Endoperoxides, Synthetic; Pulmonary Circulation; Pyrroles; Rats; Rats, Sprague-Dawley; Tetraethylammonium; Tetraethylammonium Compounds; Thromboxane A2; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 1994 |
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Cell Line; Cell Membrane; COS Cells; Diabetes Insipidus, Nephrogenic; Flow Cytometry; Humans; Intracellular Fluid; Molecular Chaperones; Morpholines; Mutagenesis; Protein Folding; Pyrroles; Receptors, Vasopressin; Spiro Compounds | 2000 |
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Animals; Anti-Anxiety Agents; Anxiety; Arginine Vasopressin; Corticotropin-Releasing Hormone; Double-Blind Method; Drug Evaluation, Preclinical; Epinephrine; Exploratory Behavior; Fear; Hydrocortisone; Hypothalamo-Hypophyseal System; Macaca mulatta; Male; Norepinephrine; Pituitary-Adrenal System; Pyrimidines; Pyrroles; Receptors, Corticotropin-Releasing Hormone; Sexual Behavior, Animal; Social Dominance; Stress, Psychological | 2000 |
Regulation of the cardiac L-type calcium channel in L6 cells by arginine-vasopressin.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Animals; Arginine Vasopressin; Barium; Calcium Channels, L-Type; Carbazoles; Cell Line; Cyclic AMP-Dependent Protein Kinases; Endothelin-1; Estrenes; GTP-Binding Proteins; Indoles; Myocardium; Protein Kinase C; Pyrroles; Pyrrolidinones; Rats | 2006 |
Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior.
Topics: Animals; Anxiety; Arginine Vasopressin; Behavior, Addictive; Benzoxazoles; Conditioning, Operant; Corticotropin-Releasing Hormone; Extinction, Psychological; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naphthyridines; Neurons; Neuropeptides; Nicotine; Orexin Receptors; Orexins; Paraventricular Hypothalamic Nucleus; Pyrimidines; Pyrroles; Receptors, Corticotropin-Releasing Hormone; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Self Administration; Tobacco Use Disorder; Urea | 2010 |
Nicotine stimulates secretion of corticosterone via both CRH and AVP receptors.
Topics: Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Corticosterone; Corticotropin-Releasing Hormone; Drug Interactions; Indoles; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Peptide Fragments; Pyrimidines; Pyrroles; Pyrrolidines; Receptors, Corticotropin-Releasing Hormone; Receptors, Vasopressin | 2012 |
The Selective Estrogen Receptor Modulator Raloxifene Regulates Arginine-Vasopressin Gene Expression in Human Female Neuroblastoma Cells Through G Protein-Coupled Estrogen Receptor and ERK Signaling.
Topics: Arginine Vasopressin; Blotting, Western; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Neuroblastoma; Phosphorylation; Protein Kinase C; Pyrroles; Quinazolines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Selective Estrogen Receptor Modulators | 2015 |